Polls and Quizzes

Dive into biosimilar regulations in the US! Test your knowledge with our quiz on FDA rules, naming tricks, postmarket safety, and more. Ready for the challenge?

Have you been keeping up with the latest market trends? Take this quiz to find out how well you know the global biosimilars market.

Explore the dynamic world of global biosimilar markets and policies! What do you know about the international biosimilar industry?

Test your knowledge of major biosimilar policies, including challenging regulatory frameworks from around the world.

Intro to Biosimilars is now in session! Test yourself on how well you know these biosimilar basics.

In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.

Alvotech has received European Commission (EC) approval to begin marketing its adalimumab biosimliar AVT02, the company announced this week.

Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.

Reverse switching occurs when patients transitioned to or initiated on a biosimilar are changed to an originator product, often because of a perceived failure in the biosimilar therapy.

When it comes to biologics, there is a constant push and pull over patent rights. Some believe this is part of a healthy market-driven economy. Others are skeptical.

With 20 biosimilar launches in the United States since 2015, opinions vary as to the strength of utilization.

Opinions are diverse on how best to clear the obstructions to biosimilar market entry and patient access.

Opinions differ on what patients are more likely to respond to.

Biosimilars are intended to save money for the health care system, but for many reasons, they are not succeeding in this mission, Harvard authors argue.

Coverage policies for biosimilars in the health care industry are the source of much angst.

Which of these selections do you think is the most powerful trend in medicine to emerge from the pandemic?

Test your knowledge of biosimilar approvals in China.

Many patient advocates hope that expansion of the Biologics Price Competition and Innovation Act (BPCIA) will bring further competition to the insulin market—and lower prices.

The court must decide whether Congress’ setting the shared responsibility payment to $0 means that the entire Affordable Care Act (ACA) statute is now unconstitutional.

Opposing interests make it hard to define what elements are essential for a competitive marketplace.

There are diverging opinions on whether comparative efficacy trials add much of value to the evidence for biosimilar approval in the United States.

How quickly and easily biosimilars should be declared interchangeable with reference products has been an ongoing issue.